DHRS3

Across TCGA pan-cancer cohorts, DHRS3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DHRS3 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher DHRS3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DHRS3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

GBM, PDAC, and CCRCC are the cancer types where DHRS3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.276	0.542	.010	14	view →
PDAC	OS	Tertile	II,III,IV	0.929	0.705	.007	12	view →
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	9	view →
LUAD	DFS	Median	All	0.821	0.981	.035	1	view →
LSCC	OS	Median	All	1.000	0.800	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DHRS3–GBM (DFS)

Open the GBM breakdown →